AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00549848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Description: See Detailed Description section for details of treatment interventions.
Study NCT00549848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Description: See Detailed Description section for details of treatment interventions.
Study NCT05346978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nasturtium (Tropaeolum majus)
Description: Freeze dried nasturtium (Edible flower)
Study NCT05346978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: collagen colored with green pigment used in the food industry
Study NCT03381820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumental folk music
Description: The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
Study NCT02504086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Support
Description: 3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
Study NCT00404417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A / Placebo
Description: Botulinum Toxin A at first injection / Placebo at second injection
Study NCT00404417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A / Botulinum Toxin A
Description: Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
Study NCT00404417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo / Botulinum Toxin A
Description: Placebo at first injection / Botulinum Toxin A at second injection
Study NCT00404417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Placebo
Description: Placebo at first injection / Placebo at second injection
Study NCT01547546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: Multiple doses
Study NCT01811706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
Study NCT01811706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally every 12 hours, for a 4 week period.
Study NCT02830906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
Study NCT02830906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
Study NCT02764944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple non-exposure EFTR
Description: This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
Study NCT00701896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline tartrate
Description: 1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
Study NCT03839914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin powder
Description: For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
Study NCT04358406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human plasma gelsolin (Rhu-pGSN)
Description: Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
Study NCT02156492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally.
Study NCT02156492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Administered orally.
Study NCT02156492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally.
Study NCT02156492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.
Study NCT04388098 — intervention group
Intervention type: OTHER
Intervention: Diagnosis of caries experience and periodontal health
Study NCT02675283 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Simtomax
Description: Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
Study NCT01319110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
Study NCT00701896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Nicotine gum and nicotine patch
Study NCT00701896 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological Control
Description: No treatment intervention only information and procedures.
Study NCT00701896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: 60 minute one-on-one Interview
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Mouthwash or bodywash
Study NCT01195883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid
Description: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
Study NCT06556316 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Intervention with the Categorization Program
Description: Cognitive intervention delivered individually. This is a hierarchical cognitive rehabilitation program
Study NCT04358406 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
Study NCT00416741 — intervention group
Intervention type: BEHAVIORAL
Intervention: Implementation of guidelines
Description: Attaining targets for LDL cholesterol, arterial blood pressure, fasting \[plasma flucose
Study NCT01195883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloid
Description: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
Study NCT03335748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training Cogmed program
Description: Cognitive training Cogmed program
Study NCT03335748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training Cogmed program
Description: Cognitive training Cogmed program
Study NCT01451411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan hydrochloride
Description: Intravenous
Study NCT01451411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study NCT03483389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol, Ethyl
Description: Randomized within-subjects design
Study NCT01867216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules
Study NCT01867216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2922470
Description: Administered orally as capsules
Study NCT02833506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02833506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02833506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant NY-ESO-1 Protein
Description: Given recombinant NY-ESO-1 protein SC
Study NCT02833506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NY-ESO-1 Protein
Description: Given recombinant NY-ESO-1 protein SC
Study NCT02833506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT00994097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
Study NCT00994097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Study NCT00994097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
Study NCT00994097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin
Description: Nasal ointment
Study NCT00994097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
Study NCT01319110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
Study NCT03173053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Shampoo
Study NCT01766570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uncontrolled nutritional intervention with a supplemental beverage
Description: Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
Study NCT01766570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04485117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index Monitor
Description: Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.
Study NCT04485117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
Study NCT04485117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia is induced inhalationally by face mask with 8% sevoflurane in 100% oxygen, then decreased to 2-3% in 40% oxygen thoroughout the operation for maintenance of anesthesia.
Study NCT04485117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia is induced by propofol (2mg/kg), then maintained using an infusion of fixed concentration (10-15 mg/kg/h) as titrated by the anesthesiologist .
Study NCT03837353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
Study NCT03837353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
Study NCT03444194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver biopsy
Description: Liver biopsy of neoplastic tissue and normal liver tissue.
Study NCT03294928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive increasing of PEEP level.
Description: four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry.
Study NCT04198896 — intervention group
Intervention type: OTHER
Intervention: incidece of cancers
Description: With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
Study NCT04694326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
Study NCT03082664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Single Use Negative Pressure Wound Therapy
Description: The PICO device will be placed over the closed cesarean section incision.
Study NCT00000607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device
Description: A type of implantable heart pump
Study NCT00000607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: (non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
Study NCT03520868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring Anti Factor Xa level
Description: Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
Study NCT00932230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KinesioTape
Description: An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
Study NCT03301532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Dietary supplementation with triheptanoin
Study NCT01929031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen + caffeine
Description: FDC tablet
Study NCT01929031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen
Description: tablet.
Study NCT01929031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen
Description: tablet
Study NCT01929031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: caffeine
Description: tablet
Study NCT01929031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen + caffeine
Description: Fixed Dose Combination (FDC) tablet
Study NCT01929031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: tablet
Study NCT04016792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily
Study NCT04016792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg SPN-812
Description: 200 mg SPN-812 will be administered once daily and compared to Placebo
Study NCT02035839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Target Temperature Management of 34°C
Description: In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
Study NCT02035839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Target Temperature Management of 32°C
Description: In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
Study NCT02035839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Target Temperature Management of 33°C
Description: In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion immediate release (IR)
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: taken orally
Study NCT03864042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: taken orally
Study NCT03483389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol, Ethyl - placebo
Description: Randomized within-subjects design
Study NCT04224519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV batch 1
Description: Type I 30 DU, Type II 32 DU, Type III 45 DU
Study NCT04224519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV batch 2
Description: Type I 30 DU, Type II 32 DU, Type III 45 DU
Study NCT04224519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV batch 3
Description: Type I 30 DU, Type II 32 DU, Type III 45 DU
Study NCT00328172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1356
Study NCT00328172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 dose 3 once daily
Description: BI 1356 dose 3 once daily
Study NCT00328172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 dose 2 once daily
Description: BI 1356 dose 2 once daily
Study NCT00328172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 dose 1 once daily
Description: BI 1356 dose 1 once daily
Study NCT00328172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin